Omega-3 Raised Brain DHA but Did Not Improve Memory or Cognition in 24-Month Trial

# What the study did

# Main findings

After six months, participants receiving omega-3 supplements showed increased DHA in cerebrospinal fluid, indicating the supplement reached a compartment closely linked to the brain. Despite that biological change, the trial recorded no improvement in memory or other measures of cognition across the full 24-month period. Brain imaging outcomes—including hippocampal volume, cortical thickness, and related structural and functional MRI measures—also showed no treatment effect.

# Why this matters practically

Many consumers take omega-3 supplements expecting cognitive protection or improvement as they age. This trial shows a clear distinction: a supplement can change a biological marker without producing a detectable functional benefit over two years in the population studied. The finding narrows the specific claim the trial tested: adding supplemental DHA to older adults with low dietary intake and dementia risk factors did not translate into better memory or brain-structure measures within the study window.

# What the study does not answer

The trial does not test whether eating omega-3–rich foods produces the same results as taking supplements. It also does not establish whether starting supplementation earlier in life, using different doses or formulations, or testing different populations (for example, people with cognitive impairment) would yield different outcomes. The results apply specifically to older adults who were cognitively unimpaired at baseline and had low dietary DHA with additional risk factors.

# Context for consumers and clinicians

Interest in omega-3 for brain health exists alongside a large commercial supplement market, often described in the billion-dollar range. DHA is a structural component of brain cells, which explains why researchers have focused on it. The trial's outcome does not deny DHA's biological role. Instead, it clarifies that raising DHA levels in cerebrospinal fluid via supplementation did not produce measurable improvements in cognition or brain imaging for this trial's participants.

# Practical takeaways

• If the goal is short- to mid-term improvement in memory or measurable brain-structure benefit for older, cognitively unimpaired adults with low DHA, this trial found no evidence that omega-3 supplements achieve that.
• The presence of higher DHA in cerebrospinal fluid confirms biological uptake but should not be interpreted as proof of cognitive benefit.
• Decisions about omega-3 intake can still consider dietary sources, long-term patterns, individual risk factors, and discussions with a clinician about alternatives or expectations.

# Bottom line